Cabozantinib Versus Sunitinib As Initial Targeted Therapy for Patients With Metastatic Renal Cell Carcinoma of Poor or Intermediate Risk: The Alliance A031203 CABOSUN Trial
- Citation:
- J Clin Oncol vol 35 (6) 591-597
- Year:
- 2017
- Type:
- Manuscript
- Funding:
- NCTN
- Endpoint:
- Primary
- Analysis:
- Primary
- Data Sharing:
- No-Data-Sharing
- Status:
- Presented/Published
- Citation Status:
- ppub
- Note:
- Methodological:
- No
- Biospecimen:
- No
- SDC:
- Yes
- Book Volume:
- 6
- Parents:
- 2533
- Children:
- None
- Pharmas:
- Grants:
- U10CA180821, U10CA180882, U10CA032291, U10CA047577, U10CA077440, U10CA077651, U10CA077658, U10CA138561, U10CA180791, U10CA180833, U10CA180850, U10CA180857, U10CA180867, P30 CA008748, U10 CA180821, U10 CA180833, U10 CA180882
- Corr. Author:
- Authors:
- Toni K. Choueiri Susan Halabi Ben L. Sanford Olwen Hahn M. Dror Michaelson Meghara K. Walsh Darren R. Feldman Thomas Olencki Joel Picus Eric J. Small Shaker Dakhil Daniel J. George Michael J. Morris
- Networks:
- CA136, KS055, LAPS-IL057, LAPS-MA036, LAPS-MO011, LAPS-NC010, LAPS-NY016, LAPS-OH007
- Study
- Alliance-A031203
- Multiple Studies, or Legacy Studies in Alliance Study:
- Phases:
- 2
- Keywords:
- Rapid Communications, Chemotherapy, Chemotherapy, ORIGINAL REPORTS, Rapid Communication